Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis.
Alta Life Sciences is a new leading venture capital investment firm headquartered in Barcelona. The investment has been made through Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC.
Recently published: Bone Health in Cancer: ESMO Clinical Practice Guidelines (2020) for practice-changing precision medicine clinical routines devoted a section to discussed on Personalized Medicine.
The co-founder of Inbiomotion (Dr. Roger Gomis) and part of the team have published the results that validated MAF test ability to identify breast cancer patients that benefit from the use of bisphosphonate in adjuvancy in a second retrospective analysis of a prospective randomized clinical trial; NSABP-B34 (NCT00009945). (Paterson et al., J Clin Oncology, 2020; doi: 10.1200/JCO.2020.38.15_suppl.513). The results were presented at the ASCO meeting 2020 (Abstract #513).
Barcelona, Spain, 2018 - Inbiomotion S.L., a biotech company specialized in the development of companion diagnostics for the use of bone modifying agents, has just announced that has been granted of access to the NSABP B34 trial by the National Cancer Institute and NRG Oncology Group, US, to validate its proprietary biomarker.
Inbiomotion SL today announced the publication of the results of the long-term follow-up of Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAFTest® in the September issue of Journal of Bone Oncology.
Read More about "Long term follow-up of Phase 3 AZURE prospective/retrospective study of MAFTest® in Journal of Bone Oncology demonstrates the survival benefit effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer"
Inbiomotion SL today announced the publication of the results of the Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAFTest® in the November issue of Lancet Oncology
Read More about "Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer"
The investment has been made through Caixa Innvierte BioMed II, a vehicle managed by Caixa Capital Risc, the venture capital arm of "la Caixa". The fund is driven by "la Caixa" and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme and has minority participation from the Institut Català de Finances.
Physicians currently have no tools to help them detect which breast cancer patients will suffer metastasis to the bone, a process that occurs in 15-20% of cases. A study led by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) and published today in JNCI has uncovered a gene that allows breast cancer cells to invade bones and create new tumours, or to metastasize.
Inbiomotion SL, a company focused on the development of a specific biomarker for the prediction of bone metastasis, has strengthened its board of directors with the appointment of Dr. David L. Lacey.